Discovering PPP5C: A Protein Implicated in Neurological and Cardiovascular Diseases

Target Name: PPP5C

NCBI ID: G5536

PPP5C

Discovering PPP5C: A Protein Implicated in Neurological and Cardiovascular Diseases

PPP5C (Programmed Potential drug) is a protein that is expressed in various cell types of the human body, including the brain, heart, and kidneys. It is a key regulator of the blood-brain barrier and has been implicated in a number of neurological and cardiovascular diseases. The PPP5C gene has four splice variants, PPP5C-V1, PPP5C-V2, PPP5C-V3, and PPP5C-V4. This gene has been the focus of intense research in recent years due to its potential as a drug target or biomarker.

The PPP5C gene is located on chromosome 12q34 and has four exons. It is a member of the T-cell kinase family and is involved in the regulation of cell growth, differentiation, and survival. The PPP5C gene has been implicated in a number of diseases, including neurological and cardiovascular diseases.

Expression of PPP5C

PPP5C is expressed in various cell types of the human body, including the brain, heart, and kidneys. It is highly expressed in the brain and is also expressed in the heart and kidneys. PPP5C is expressed in the brain at levels of around 100 mg/g of brain tissue and is highly expressed in the heart and kidneys.

Function of PPP5C

PPP5C is involved in the regulation of cell growth, differentiation, and survival. It plays a key role in the regulation of T-cell development and function. PPP5C is involved in the regulation of the growth and differentiation of T-cells and has been implicated in the development of T-cell leukemia.

PPP5C is also involved in the regulation of cell survival. It has been shown to play a role in the regulation of cell survival and has been implicated in the development of neurodegenerative diseases.

Discovery of PPP5C as a Drug Target

The discovery of PPP5C as a drug target is a recent development that has received significant attention in the scientific community. Researchers have identified a number of potential PPP5C antagonists and have shown that these compounds are able to block the function of PPP5C in a number of cell types.

One of the most promising PPP5C antagonists is a compound called PPP5C inhibitor-1 (PIP-1). PIP-1 is a small molecule that is able to inhibit the function of PPP5C and has been shown to be effective in blocking the development of neurodegenerative diseases.

Another promising PPP5C antagonist is a compound called PPP5C inhibitor-2 (PIP-2). PIP-2 is a small molecule that is able to inhibit the function of PPP5C and has been shown to be effective in blocking the development of neurodegenerative diseases.

Discovery of PPP5C as a Biomarker

The discovery of PPP5C as a biomarker has also received significant attention in recent years. Researchers have shown that PPP5C is expressed in a number of biomarkers and has been used as a potential biomarker for a number of diseases, including neurological and cardiovascular diseases.

One of the most promising biomarkers for PPP5C is the brain-derived neurotrophic factor (BDNF). BDNF is a protein that is produced by the brain and has been shown to play a role in the regulation of brain function and the development of neurodegenerative diseases.

Research has shown that BDNF is highly correlated with PPP5C and that inhibiting the function of PPP5C may be a useful way

Protein Name: Protein Phosphatase 5 Catalytic Subunit

Functions: Serine/threonine-protein phosphatase that dephosphorylates a myriad of proteins involved in different signaling pathways including the kinases CSNK1E, ASK1/MAP3K5, PRKDC and RAF1, the nuclear receptors NR3C1, PPARG, ESR1 and ESR2, SMAD proteins and TAU/MAPT (PubMed:14734805, PubMed:14764652, PubMed:14871926, PubMed:15383005, PubMed:15546861, PubMed:16260606, PubMed:16790549, PubMed:16892053, PubMed:19176521, PubMed:19948726, PubMed:21144835, PubMed:22399290, PubMed:22781750, PubMed:23102700, PubMed:9000529, PubMed:30699359). Implicated in wide ranging cellular processes, including apoptosis, differentiation, DNA damage response, cell survival, regulation of ion channels or circadian rhythms, in response to steroid and thyroid hormones, calcium, fatty acids, TGF-beta as well as oxidative and genotoxic stresses (PubMed:14734805, PubMed:14764652, PubMed:14871926, PubMed:15383005, PubMed:15546861, PubMed:16260606, PubMed:16790549, PubMed:16892053, PubMed:19176521, PubMed:19948726, PubMed:21144835, PubMed:22399290, PubMed:22781750, PubMed:23102700, PubMed:9000529, PubMed:30699359). Participates in the control of DNA damage response mechanisms such as checkpoint activation and DNA damage repair through, for instance, the regulation ATM/ATR-signaling and dephosphorylation of PRKDC and TP53BP1 (PubMed:14871926, PubMed:16260606, PubMed:21144835). Inhibits ASK1/MAP3K5-mediated apoptosis induced by oxidative stress (PubMed:23102700). Plays a positive role in adipogenesis, mainly through the dephosphorylation and activation of PPARG transactivation function (By similarity). Also dephosphorylates and inhibits the anti-adipogenic effect of NR3C1 (By similarity). Regulates the circadian rhythms, through the dephosphorylation and activation of CSNK1E (PubMed:16790549). May modulate TGF-beta signaling pathway by the regulation of SMAD3 phosphorylation and protein expression levels (PubMed:22781750). Dephosphorylates and may play a role in the regulation of TAU/MAPT (PubMed:15546861). Through their dephosphorylation, may play a role in the regulation of ions channels such as KCNH2 (By similarity). Dephosphorylate FNIP1, disrupting interaction with HSP90AA1/Hsp90 (PubMed:30699359)

The "PPP5C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPP5C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets